Yushin Company (6482) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
21 Jul, 2026Executive summary
Net sales for the nine months ended December 31, 2025, declined 10.8% year-over-year to ¥16,748 million, with operating profit down 78.4% to ¥303 million and profit attributable to owners of parent down 74.8% to ¥244 million, impacted by higher personnel and R&D expenses and raw material costs.
Orders received increased 8.9% year-over-year, mainly for custom-designed machines, but net sales remained sluggish.
The global economic environment remained uncertain due to U.S. tariff policies and rising energy and raw material prices.
Financial highlights
Gross profit for the nine months was ¥6,424 million, down from ¥7,497 million year-over-year.
Comprehensive income decreased 9.5% year-over-year to ¥1,202 million.
Basic earnings per share dropped to ¥7.20 from ¥28.50 year-over-year.
Total assets as of December 31, 2025, were ¥40,486 million, down ¥559 million from March 31, 2025.
Net assets increased slightly to ¥35,572 million, with an equity ratio of 86.9%.
Outlook and guidance
Full-year consolidated earnings forecasts for FY2026 remain unchanged: net sales of ¥23,000 million (down 12.0% year-over-year), operating profit of ¥1,500 million (down 42.0%), and profit attributable to owners of parent of ¥1,000 million (down 40.9%).
Annual dividend forecast is ¥20 per share.
Latest events from Yushin Company
- Sales and operating profit surged, but ordinary profit fell on forex losses; outlook steady.6482
Q2 202521 Jul 2026 - Sales surged 19.7% year-over-year, but profit margins narrowed on higher costs.6482
Q1 202521 Jul 2026 - Net sales and profit grew in FY2025, but FY2026 guidance signals declines amid global uncertainty.6482
Q4 202521 Jul 2026 - Net sales rose 14.5% year-over-year, with robust growth in Japan and Europe.6482
Q3 202521 Jul 2026 - Operating profit rose despite lower sales, with Asia growth offset by Europe weakness.6482
Q1 202621 Jul 2026 - Profits fell sharply on weak medical equipment sales, but dividends and buybacks are maintained.6482
Q2 202621 Jul 2026 - Profits and sales fell sharply in FY2026, but a strong rebound is forecast for FY2027.6482
Q4 202621 Jul 2026